Recent health news includes trade restrictions on Brazilian chicken due to bird flu, potential U.S. tariffs on ...

Novo Nordisk will lose its patent protection on its branded semaglutide drugs Ozempic and Wegovy in Canada after not paying a ...

NEW YORK CITY, NY / ACCESS Newswire / July 9, 2025 / Semaglutide is making waves as the powerhouse ingredient in Ozempic and ...

The high dose of Wegovy is one part of Novo Nordisk's plan to defend its obesity business, along with a major ...

Under the agreement, the two institutions will co-develop programmes across three key areas: health system capacity building, ...

Novo Nordisk is a global diabetes and weight loss leader with strong long-term growth prospects. Read why NVO stock is a ...

Denmark: Following a recent World Health Organization (WHO) alert on semaglutide-containing medicines, Novo Nordisk has ...

Novo Nordisk A/S (NYSE:NVO) is one of the 11 Best Foreign Stocks to Buy According to Hedge Funds. On June 18, TD Cowen ...

Analysts said the deal with Novo was likely giving Hims “‘credibility’ or increased consumer traffic,” adding that the ...

Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging ...

Technology will soon make it possible to develop cheap, widely accessible psychoactive substances that are not harmful in the ...

Cogent's bezuclastinib showed strong efficacy in a non-advanced SM trial, with a planned FDA submission expected by the end ...